13 September 2017 – Helsinki University Hospital has invested in the RayPilot® system. The system has been used and evaluated in extreme hypofractionated prostate cancer treatment at the clinic during the last 3 years.

"We are proud that Helsinki University Hospital has invested in our RayPilot system. They already have several competing tracking system and we interpret this as saying that our system adds something beyond what other tracking systems can offer. Representatives from the radiotherapy department state that they prefer RayPilot to the patients that undergo extreme hypofractionated prostate treatment” says Tomas Gustafsson, CEO of Micropos Medical.

Helsinki University Hospital has been reference clinic for RayPilot since 2014 and has, for example, been invited to present its positive experiences of the system at a number of radiotherapy users meetings. In addition, several European clinics and distributors have visited the clinic for training and on-site learning about the system.

The clinic uses RayPilot for motion surveillance in extreme hypofractionated protocol of prostate cancer patients with 5 sessions a 7 Gy. As soon as the motion exceeds 3 mm they gate the beam.

The RayPilot system is used for both tracking the prostate motion during the set-up procedure in order to make sure that the CBCT acquisition is valid and for tracking the motion in 30 Hz continuously during the VMAT treatment.

About Micropos Medical AB (publ):

Micropos Medical AB (publ) (www.micropos.se) is a Swedish company that has developed the RayPilot® system, which is an electromagnetic positioning and real time tracking system for a fast and objective set-up and for continuous localisation during radiotherapy. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; one transmitter that is placed close by the tumor, a receiving system that is placed directly on the treatment couchtop and software that continuously shows the precise tumor location, and hence where to focus the linac beam. RayPilot® has a unique gating solution qualified and compatible for use with Varian’s Clinac® iX linear accelerators and Trilogy® systems. Micropos develops an upcoming RayPilot® transmitter for positioning, in-situ dosimetry and automatic patient identification. RayPilot® is CE certified for prostate and surface use. Follow us on Facebook, www.facebook.com/MicroposMedical. The Micropos share is traded under the stock ticker MPOS.

• Micropos Medical